Reply

Affiliations

¹ Hepato-Gastroenterology Department, Institut Mutualiste Montsouris and Hepato-Gastroenterology Department, Saint-Louis Hospital APHP, Paris, France.
² Hepato-Gastroenterology Department, Claude Huriez Hospital, University of Lille 2, Lille, France.
³ Hepato-Gastroenterology Department, Saint-Louis Hospital APHP, Paris, France.

Comment

Marion Simon et al. Clin Gastroenterol Hepatol. 2017 Jan.

. 2017 Jan;15(1):148-149.

doi: 10.1016/j.cgh.2016.09.016. Epub 2016 Sep 17.

¹ Hepato-Gastroenterology Department, Institut Mutualiste Montsouris and Hepato-Gastroenterology Department, Saint-Louis Hospital APHP, Paris, France.
² Hepato-Gastroenterology Department, Claude Huriez Hospital, University of Lille 2, Lille, France.
³ Hepato-Gastroenterology Department, Saint-Louis Hospital APHP, Paris, France.

No abstract available

Comment on

Long-term Outcomes of Thalidomide Therapy for Adults With Refractory Crohn's Disease.
Simon M, Pariente B, Lambert J, Cosnes J, Bouhnik Y, Marteau P, Allez M, Colombel JF, Gornet JM. Simon M, et al. Clin Gastroenterol Hepatol. 2016 Jul;14(7):966-972.e2. doi: 10.1016/j.cgh.2015.10.034. Epub 2015 Nov 18. Clin Gastroenterol Hepatol. 2016. PMID: 26598226
Thalidomide in Refractory Crohn's Disease: Risk-Benefit Ratio.
El-Matary W. El-Matary W. Clin Gastroenterol Hepatol. 2017 Jan;15(1):148. doi: 10.1016/j.cgh.2016.08.019. Epub 2016 Aug 21. Clin Gastroenterol Hepatol. 2017. PMID: 27552856 No abstract available.